Company Overview

The Cooper Companies, Inc., together with its subsidiaries, is a global medical device company headquartered in San Ramon, CA. Founded in 1958, the company develops, manufactures, and markets products primarily for contact lens wearers and focuses on women's health. It operates through two distinct business segments: CooperVision and CooperSurgical. The company's products positively impact over fifty million lives each year, supported by a workforce of more than 16,000 employees who sell products in over 130 countries.

Business Segments Overview

The Cooper Companies operates through two main segments, each catering to specific healthcare needs:

CooperVision

This segment is a pure-play contact lens business that develops, manufactures, and markets a comprehensive range of products for contact lens wearers. Its portfolio includes:

- Toric lenses: Correcting astigmatism.

- Multifocal lenses: Addressing presbyopia (age-related farsightedness).

- Spherical lenses: Correcting myopia (nearsightedness) and hyperopia (farsightedness).

CooperVision's products are designed to solve vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigue.

CooperSurgical

This segment focuses on family and women's health care. It provides a wide array of products and services including:

- Fertility products and services: Supporting individuals and couples undergoing fertility treatments.

- Medical devices: Including surgical and office products like the Paragard contraceptive intrauterine devices.

- Contraception: Offering various family planning solutions.

- Cryostorage: Services such as cord blood and cord tissue storage, offered to healthcare professionals and patients worldwide.

- Genomic services: Including genetic testing.

Financial Performance & Market Position

The Cooper Companies has established itself as a leading global medical device company with a strong market presence in its specialized sectors. As of September 15, 2025, the company holds a market capitalization of $13.26 Billion.

Recent Financial Results

- Q3 2025 Results (Ended July 2025):

- Revenue reported at $1.06 billion, a year-over-year increase of 5.7%.

- Diluted EPS was $1.10, up from $0.96 in the same period last year.

- CooperVision revenue grew 6% to $718.4 million.

- CooperSurgical revenue rose 4% to $341.9 million.

- The company generated strong margins and robust free cash flow of $164.6 million.

- Q2 2025 Results (Ended April 2025):

- Revenue increased 6% year-over-year to $1,002.3 million.

- CooperVision (CVI) revenue was up 5% to $669.6 million.

- CooperSurgical (CSI) revenue was up 8% to $332.7 million.

- Non-GAAP diluted EPS was $0.96, an increase of $0.11 (14%) from the prior year's second quarter.

- Full Year 2024 Results:

- Total revenue was $3.90 billion, an increase of 8.41% compared to $3.59 billion in the previous year.

- Net earnings reached $392.30 million, showing a significant increase of 33.34%.

Updated Fiscal 2025 Guidance

The company has updated its fiscal 2025 guidance, projecting total revenue to be between $4,076 million and $4,096 million, with expected organic growth of 4-4.5%. Non-GAAP diluted EPS is forecasted to be between $4.08 and $4.12.

Market Leadership & Global Presence

Cooper Companies is recognized as one of the leading visioncare companies globally and a major eyecare company in the United States. Its established track record in product development underpins its leadership in the vision care market. With its headquarters in San Ramon, CA, the company maintains a vast global reach, distributing its products in over 130 countries and impacting millions of lives annually.

Product Portfolio & Innovation

CooperVision Product Innovation

The CooperVision segment is dedicated to advancing contact lens technology. Its product development focuses on addressing a wide spectrum of vision correction needs, including specialized lenses for astigmatism, presbyopia, and myopia, as well as solutions for ocular dryness and eye fatigue.

CooperSurgical Product Innovation

CooperSurgical is committed to advancing women's health and reproductive care. Its portfolio includes innovative solutions for fertility, contraception, and diagnostic services. Key offerings include the Paragard contraceptive intrauterine devices, cryostorage services for biological materials, and advanced genomic testing services.

Capital Allocation Strategy

Cooper Companies actively manages its capital to enhance shareholder value.

- During Q3, the company repurchased $52.1 million of common stock at an average price of $71.97.

- As of September 2025, Cooper Companies announced an increase of $1 billion to its share repurchase program.

Stock Performance & Volatility

- Volatility: COO stock exhibits 2.26% volatility.

- Beta: The stock has a beta coefficient of 0.79, indicating it is less volatile than the broader market.

- Historical Prices:

- All-Time High: $115.90 USD (September 3, 2021)

- All-Time Low: $0.11 USD (July 20, 1993)

- Dividend Information:

- 2024: Dividend yield was 0.00%, with a payout ratio of 0.00%.

- 2023: Dividend yield was 0.02%, with a payout ratio of 1.02%.

The Cooper Companies continues to maintain its position as a leading global medical device company, focusing on improving lives through its innovative contact lens and women's healthcare solutions across its extensive international footprint.